Results 31 to 40 of about 25,780 (241)

A phase I and pharmacokinetic study of intraperitoneal topotecan [PDF]

, 2001
Purpose: To evaluate the feasibility and pharmacology of intraperitoneal (IP) topotecan. Patients and methods: Fifteen patients with recurrent ovarian cancer in a phase I trial were treated with escalating IP topotecan doses (5-30 mg/m(2)) for ...
van der Zee, AGJ, Beijnen, JH, A M E Bos, N H Mulder, L S Hofstra, P H B Willemse, Rosing, H, A G J van der Zee, de Vries, EGE; id_orcid, Hofstra, LS, Willemse, PHB, de Vries, EGE, J H Beijnen, J G Aalders, Mulder, NH, Aalders, JG, E G E de Vries, H Rosing   +17 more
core   +5 more sources

Continuous and bolus intraventricular topotecan prolong survival in a mouse model of leptomeningeal medulloblastoma.

PLoS ONE, 2019
Leptomeningeal metastasis remains a difficult clinical challenge. Some success has been achieved by direct administration of therapeutics into the cerebrospinal fluid (CSF) circumventing limitations imposed by the blood brain barrier.
Gregory M Shackleford, Min Y Mahdi, Rex A Moats, Debra Hawes, Hung C Tran, Jonathan L Finlay, Tuan Q Hoang, Ellis F Meng, Anat Erdreich-Epstein   +8 more
doaj   +1 more source

Systematic Review of topotecan (Hycamtin) in relapsed small cell lung cancer

BMC Cancer, 2010
Background To undertake a systematic review of the available data for oral and intravenous topotecan in adults with relapsed small cell lung cancer (SCLC) for whom re-treatment with the first line regimen is not considered appropriate.
Riemsma Rob, Simons Jean P, Bashir Zahid, Gooch Caroline L, Kleijnen Jos   +4 more
doaj   +1 more source

Delayed vaccine-induced CD8+ T cell expansion by topoisomerase I inhibition mediates enhanced CD70-dependent tumor eradication

Journal for ImmunoTherapy of Cancer, 2023
Background The survival of patients with cervical cancer who are treated with cisplatin in conjunction with the topoisomerase I inhibitor topotecan is enhanced when compared with patients treated with only one of these chemotherapeutics.
Sjoerd H van der Burg, Suzanne van Duikeren, Ramon Arens, Cornelis J M Melief, Tetje C van der Sluis, Ward Vleeshouwers, Floortje J van Haften, Iris N Pardieck, J Fréderique de Graaf, Koen van der Maaden   +9 more
doaj   +1 more source

Kinetic modelling of the role of the aldehyde dehydrogenase enzyme and the breast cancer resistance protein in drug resistance and transport [PDF]

, 2011
A compartmental model for the in vitro uptake kinetics of the anti-cancer agent topotecan (TPT) has been extended from a previously published model. The extended model describes the drug activity and delivery of the pharmacologically active form to the ...
N.D. Evans, Evans, Neil D., M.J. Chappell, Errington, Rachel J., R.J. Errington, Smith, Paul J., Smith, Paul James, Atari, M. I., Chappell, M. J., P.J. Smith, Chappell, M. J. (Michael J.), M.I. Atari, Errington, Rachel Jane, Evans, N. D.   +13 more
core   +1 more source

The inhibition of autophagy sensitises colon cancer cells with wild-type p53 but not mutant p53 to topotecan treatment.

PLoS ONE, 2012
BackgroundTopotecan produces DNA damage that induces autophagy in cancer cells. In this study, sensitising topotecan to colon cancer cells with different P53 status via modulation of autophagy was examined.Methodology/principal findingsThe DNA damage ...
Dan-Dan Li, Ting Sun, Xiao-Qi Wu, Shu-Peng Chen, Rong Deng, Shan Jiang, Gong-Kan Feng, Jing-Xuan Pan, Xiao-Shi Zhang, Yi-Xin Zeng, Xiao-Feng Zhu   +10 more
doaj   +1 more source

Carboplatin +/- topotecan ophthalmic artery chemosurgery for intraocular retinoblastoma. [PDF]

PLoS ONE, 2013
PURPOSE: Carboplatin administered systemically or periocularly can result in dramatic and prompt regression of retinoblastoma. However, both routes are rarely curative alone and have undesirable side effects.
Jasmine H Francis, Y Pierre Gobin, Ira J Dunkel, Brian P Marr, Scott E Brodie, Gowtham Jonna, David H Abramson   +6 more
doaj   +1 more source

Structural and dynamical effects induced by the anticancer drug topotecan on the human topoisomerase I - DNA complex. [PDF]

PLoS ONE, 2010
BACKGROUND: Human topoisomerase I catalyzes the relaxation of DNA supercoils in fundamental cell processes like transcription, replication and chromosomal segregation. It is the only target of the camptothecin family of anticancer drugs.
Giordano Mancini, Ilda D'Annessa, Andrea Coletta, Nico Sanna, Giovanni Chillemi, Alessandro Desideri   +5 more
doaj   +1 more source

Lesser Toxicities of Belotecan in Patients with Small Cell Lung Cancer: A Retrospective Single-Center Study of Camptothecin Analogs

Canadian Respiratory Journal, 2016
Purpose. Topotecan and belotecan are camptothecin derivatives that are used to treat small cell lung cancer (SCLC). This study compared the toxicities and efficacies of belotecan and topotecan monotherapies in patients with SCLC. Methods.
Yeon Hee Park, Chae Uk Chung, Bo Mi Park, Myoung Rin Park, Dong Il Park, Jae Young Moon, Hee Sun Park, Jin Hwan Kim, Sung Soo Jung, Ju Ock Kim, Sun Young Kim, Jeong Eun Lee   +11 more
doaj   +1 more source

RESILIENT Part 2: A Randomized, Open-Label Phase III Study of Liposomal Irinotecan Versus Topotecan in Adults With Relapsed Small Cell Lung Cancer

Journal of Clinical Oncology
PURPOSE The phase III RESILIENT trial compared second-line liposomal irinotecan with topotecan in patients with small cell lung cancer (SCLC). PATIENTS AND METHODS Patients with SCLC and progression on or after first-line platinum-based chemotherapy were
D. Spigel, Afshin Dowlati, Yuan-Bin Chen, A. Navarro, J. Yang, Goran Stojanovic, Maria Jove, Patricia Rich, Z. Andrić, Yi-Long Wu, C. Rudin, Huanyu Chen, Li Zhang, Stanley Yeung, F. Benzaghou, L. Paz-Ares, P. Bunn   +16 more
semanticscholar   +1 more source